Legal Representation
Attorney
Lisa M. Tittemore
USPTO Deadlines 1 active
| Deadline Type | Event Code | Deadline Date | Days Until | Priority | Extension Available |
|---|---|---|---|---|---|
|
MAINTENANCE
Section 8 & 9 (30-Year) Renewal Due (Based on registration date 2002-06-11) |
R.PRA | Jun 11, 2032 | 2531 days | Critical | No |
Next deadline: Section 8 & 9 (30-Year) Renewal Due (Based on registration date 2002-06-11)
on June 11, 2032
(2531 days)
Application History
39 events| Date | Code | Type | Description |
|---|---|---|---|
| Jan 26, 2022 | NA89 | E | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED |
| Jan 26, 2022 | RNL2 | Q | REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS) |
| Jan 26, 2022 | 89AG | O | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED |
| Jan 26, 2022 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| Aug 17, 2021 | E89R | I | TEAS SECTION 8 & 9 RECEIVED |
| Jun 11, 2021 | REM2 | E | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED |
| Feb 10, 2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Jan 14, 2014 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Jan 14, 2014 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Jun 12, 2012 | NA89 | E | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED |
| Jun 12, 2012 | RNL1 | Q | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) |
| Jun 12, 2012 | 89AG | O | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED |
| Jun 11, 2012 | E89R | I | TEAS SECTION 8 & 9 RECEIVED |
| Nov 24, 2009 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Jul 1, 2008 | C15A | O | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. |
| Jun 24, 2008 | PLGL | A | ASSIGNED TO PARALEGAL |
| Jun 11, 2008 | E815 | I | TEAS SECTION 8 & 15 RECEIVED |
| Sep 18, 2007 | CFIT | O | CASE FILE IN TICRS |
| Jun 11, 2002 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Nov 4, 2001 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Nov 4, 2001 | DOCK | D | ASSIGNED TO EXAMINER |
| Oct 24, 2001 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
| Sep 15, 2001 | IUAF | S | USE AMENDMENT FILED |
| Apr 12, 2001 | EX5G | S | SOU EXTENSION 5 GRANTED |
| Mar 12, 2001 | EXT5 | S | SOU EXTENSION 5 FILED |
| Nov 24, 2000 | EX4G | S | SOU EXTENSION 4 GRANTED |
| Sep 11, 2000 | EXT4 | S | SOU EXTENSION 4 FILED |
| May 10, 2000 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Mar 15, 2000 | EXT3 | S | SOU EXTENSION 3 FILED |
| Sep 15, 1999 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Sep 15, 1999 | EXT2 | S | SOU EXTENSION 2 FILED |
| Apr 2, 1999 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Mar 11, 1999 | EXT1 | S | SOU EXTENSION 1 FILED |
| Sep 15, 1998 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT |
| Jun 23, 1998 | PUBO | A | PUBLISHED FOR OPPOSITION |
| May 22, 1998 | NPUB | O | NOTICE OF PUBLICATION |
| Mar 30, 1998 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Mar 24, 1998 | CNEA | F | EXAMINER'S AMENDMENT MAILED |
| Mar 10, 1998 | DOCK | D | ASSIGNED TO EXAMINER |
Detailed Classifications
Class 005
pharmaceutical preparations for the diagnosis, treatment or prevention of [ conditions or diseases of the central nervous system or peripheral nervous system, neurologic disorders, neurodegenerative disorders, ] hepatitis-C, [ cancer, multi-drug resistance,] autoimmune diseases [, and HIV infection and AIDS ]
First Use Anywhere:
Apr 26, 1999
First Use in Commerce:
Apr 26, 1999
Class 042
pharmaceutical research services for others
First Use Anywhere:
Feb 23, 1998
First Use in Commerce:
Feb 23, 1998
Classification
International Classes
005
042